Ascending colon cancer HER2 (-) is a transmembrane protein in ascending colon cancer HER2 is negative, has lower invasiveness and lower recurrence and metastasis rates compared to positive patients, but does not benefit from medications for anti-HER2 therapy.
HER2 is a transmembrane protein that is a major test for breast cancer patients. HER2-positive breast cancer patients have higher invasiveness and higher recurrence and metastasis rates compared to negative patients, but positive patients have better results from anti-HER2 therapy drugs (e.g., trastuzumab), which can be effective in improving prognosis.
In addition to breast cancer, HER2 is gradually being detected and emphasized in other cancer types, including colon cancer. Ascending colon cancer belongs to the right half of colon cancer, HER2 (-) represents the transmembrane protein HER2 is negative, compared with the positive patients tumor invasiveness, recurrence rate, metastasis rate is lower, the prognosis is better, but can not benefit from the anti-HER2 treatment of drugs.
Although doctors have begun to pay attention to HER2 in colon cancer, anti-HER2 therapy has not yet become the standard of care for colon cancer.
It is recommended that ascending colon cancer HER2-negative patients should visit the hospital in time and be treated under the guidance of their doctors, so as to avoid delays in early detection and early treatment.